Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma

NCT01129180 is registered in ClinicalTrials.gov with Pierluigi Porcu as lead sponsor.

NCT NCT01129180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01129180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma
Lead sponsor
Pierluigi Porcu
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
December 31, 2012
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult nasal type extranodal nk/t-cell lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, hepatosplenic t-cell lymphoma, peripheral t-cell lymphoma, post-transplant lymphoproliferative disorder, prolymphocytic leukemia, recurrent adult t-cell leukemia/lymphoma, recurrent cutaneous t-cell non-hodgkin lymphoma, recurrent mycosis fungoides/sezary syndrome, small intestine lymphoma, t-cell large granular lymphocyte leukemia